United States medical laboratories industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Medical Laboratories Stocks in USA: Revenue Cohort 2

Name: Medical Laboratories Stocks in USA: Revenue Cohort 2 comparison snapshot
Creator: Fliar BI Prism

A five-company medical laboratories cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderBiodesix · 53

Strongest available pathVeracyte · -7.0%

Widest latest marginVeracyte · 12.8%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1BDSX · Nasdaq

Biodesix

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 2005Boulder, Colorado$278.0M market cap

View full Companies Radar profile

53Moderate

Snapshot price$26.34as of page date

Monthly-close return-84.0%five-year window

FY2025 revenue$0.09BBIODESIX INC

Net margin-39.8%FY2025

Prism attention17.9%share across these five

Filing track recordRevenue, USD billions

+62.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.9%

52-week position81% through range

$5.26$31.31

News mentions909

Community mentions8partial coverage

U.S.-scope patents225

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal69/100
Management stability90/100
Market position3/100
Capital-event signal75/100
Innovation pulse9/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2VCYT · Nasdaq

Veracyte

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 2008San Francisco, California$3.47B market cap

View full Companies Radar profile

52Moderate

Snapshot price$43.19as of page date

Monthly-close return-7.0%five-year window

FY2025 revenue$0.52BVERACYTE, INC.

Net margin12.8%FY2025

P/E snapshot30.9xone ratio, not a verdict

Prism attention32.6%share across these five

Filing track recordRevenue, USD billions

+135.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 23.9%

52-week position44% through range

$29.38$60.91

News mentions1.7K

Community mentions21partial coverage

U.S.-scope patents221

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal74/100
Management stability90/100
Market position5/100
Capital-event signal67/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3CSTL · Nasdaq

Castle Biosciences

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 2008Friendswood, Texas$1.01B market cap

View full Companies Radar profile

39Cautious

Snapshot price$33.03as of page date

Monthly-close return-50.3%five-year window

FY2025 revenue$0.34BCASTLE BIOSCIENCES INC

Net margin-7.0%FY2025

P/E snapshot-33.4xone ratio, not a verdict

Prism attention24.5%share across these five

Filing track recordRevenue, USD billions

+265.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 38.3%

52-week position58% through range

$17.72$44.28

News mentions1.2K

Community mentions24partial coverage

U.S.-scope patents83

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal42/100
Management stability90/100
Market position10/100
Capital-event signal46/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4PSNL · Nasdaq

Personalis

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 2011Menlo Park, California$1.79B market cap

View full Companies Radar profile

34Cautious

Snapshot price$16.78as of page date

Monthly-close return-12.8%five-year window

FY2025 revenue$0.07BPersonalis, Inc.

Net margin-116.7%FY2025

P/E snapshot-17.8xone ratio, not a verdict

Prism attention22.2%share across these five

Filing track recordRevenue, USD billions

-18.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -5.0%

52-week position85% through range

$4.67$18.89

News mentions1.1K

Community mentions40partial coverage

U.S.-scope patents165

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position3/100
Capital-event signal39/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 7 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5AMS · NYSE

American Shared Hospital Services

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 1980San Francisco, California$9.6M market cap

View full Companies Radar profile

31Cautious

Snapshot price$1.44as of page date

Monthly-close return-47.8%five-year window

FY2025 revenue$0.03BAMERICAN SHARED HOSPITAL SERVICES

Net margin-5.5%FY2025

Prism attention2.8%share across these five

Filing track recordRevenue, USD billions

+59.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.3%

52-week position10% through range

$1.25$3.11

News mentions141

Community mentions0partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position5/100
Capital-event signal0/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Veracyte

-7.0%

Personalis

-12.8%

American Shared Hospital Services

-47.8%

Castle Biosciences

-50.3%

Biodesix

-84.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Veracyte

$0.52B

Castle Biosciences

$0.34B

Biodesix

$0.09B

Personalis

$0.07B

American Shared Hospital Services

$0.03B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Veracyte

12.8%

American Shared Hospital Services

-5.5%

Castle Biosciences

-7.0%

Biodesix

-39.8%

Personalis

-116.7%

Prism news attention

Normalized share across these five names; attention is not quality.

Veracyte

32.6%

Castle Biosciences

24.5%

Personalis

22.2%

Biodesix

17.9%

American Shared Hospital Services

2.8%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized medical laboratories news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Veracyte leads the conversation

It holds 32.6% of measured medical laboratories news attention and also carries the basket's largest revenue base at $0.52B.

Price path

Veracyte leads the available price paths

Its monthly-close return is -7.0% for the five-year window. At the other end, Biodesix is -84.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Veracyte has the widest latest margin

Its FY2025 net margin is 12.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Castle Biosciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -33.4x while its five-year window price return is -50.3%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · BDSX

Biodesix

909available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+96.1%149 latest 12m vs 76 prior 12m

Machine-classified coverage tone

92.8% positive-4.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 16cancer biomarkers 15stock price 15biomarkers early lung cancer 13screening eligibility lung cancer 13lung cancer screening guidelines 13ldct lung screening 12lung cancer risk assessment 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-04-19–2026-06-07 · trend and themes shown through 2026-06

Areas of research · VCYT

Veracyte

1,655available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+50.6%351 latest 12m vs 233 prior 12m

Machine-classified coverage tone

96.7% positive+0.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cancer biomarkers 59stock performance 31age prostate cancer 24obesity prostate cancer 22biomarker discovery 20diet prostate cancer 20african ancestry prostate cancer 20vascetomy prostate cancer 19

Keyword tag occurrences in available Prism news records.

Coverage: 2010-06-10–2026-06-06 · trend and themes shown through 2026-06

Areas of research · CSTL

Castle Biosciences

1,244available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Leadership & governance

Capital allocation & transactions

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-26.2%169 latest 12m vs 229 prior 12m

Machine-classified coverage tone

82.6% positive-11.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

uv index melanoma 40sunscreen melanoma 36spf melanoma prevention 35photoprotection melanoma 29tanning beds melanoma 29uv radiation melanoma 25sunburn melanoma 25barrett's esophagus 16

Keyword tag occurrences in available Prism news records.

Coverage: 2012-01-25–2026-06-01 · trend and themes shown through 2026-06

Areas of research · PSNL

Personalis

1,130available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+33.5%251 latest 12m vs 188 prior 12m

Machine-classified coverage tone

96.8% positive+3.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

circulating tumor dna 69liquid biopsy sensitivity 45blood-based screening 39ctdna analysis 23cancer biomarkers 20stock performance 18screening eligibility lung cancer 16lung cancer screening guidelines 16

Keyword tag occurrences in available Prism news records.

Coverage: 2011-12-06–2026-06-05 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

PSNL

Personalis

40 mentions

Products, pricing and logistics

Stock and valuation

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 40 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

BDSX

Biodesix

through 2026-05-05

Earnings releases 31Company announcements 5Asset acquisitions 1

2026-05-05
Earnings releases
The company beat the consensus Wall Street estimate of $23.2 million.
2026-01-27
Asset acquisitions
Director Jack Schuler acquired 82,465 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd.
2025-10-30
Company announcements
On Tuesday, the Louisville, Colorado-based developer of oncology tests marked five years of being listed on the Nasdaq by ringing the closing bell at the exchange.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VCYT

Veracyte

through 2026-02-25

Earnings releases 23Company announcements 2Leadership changes 2Listing / IPO 1

2026-02-25
Earnings releases
Total revenue for the fourth quarter of 2025 was $140.6 million , an increase of 19% compared to $118.6 million reported in the fourth quarter of 2024.
2025-02-14
Listing / IPO
Veracyte Inc. closed its public offering generating net proceeds of about $55.1 million.
2024-09-05
Leadership changes
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, recently announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CSTL

Castle Biosciences

through 2026-03-01

Earnings releases 38Company announcements 6Leadership changes 3Lawsuits 2M&A 1

2026-03-01
Earnings releases
Castle reported FY2025 revenue of $344M (above guidance)
2025-02-14
M&A
Castle Biosciences Inc. is acquiring gastrointestinal (GI) diagnostics company Cernostics Inc. in a transaction valued up to $80 million.
2024-12-19
Company announcements
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material to their entering into employment with Castle Biosciences.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PSNL

Personalis

through 2025-11-03

Earnings releases 17Company announcements 5Leadership changes 5Asset acquisitions 1

2025-11-03
Company announcements
Personalis last month announced new data from an AstraZeneca Phase 3 clinical trial in lung cancer that demonstrated its NeXT Personal molecular residual disease test served as a useful tool in assessing the maintenance treatment response post‑CRT in patients with unresectable stage III, EGFR‑mutated non‑small cell lung cancer.
2025-08-06
Earnings releases
declined 26.1% to $4.17 in pre-market trading after the company reported a second-quarter revenue miss and cut its FY25 sales guidance.
2024-08-16
Asset acquisitions
Personalis, Inc. has struck a deal with Tempus AI, Inc., selling 3.5 million shares of its common stock at $5.07 each, adding up to over $17.7 million in gross proceeds. Additionally, Tempus exercised warrants for another 9.2 million shares, bringing in an extra $18.4 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AMS

American Shared Hospital Services

through 2026-03-24

Earnings releases 14Leadership changes 3Company announcements 2M&A 1

2026-03-24
Earnings releases
American Shared Hospital Services, a provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, will hold a conference call on March 31st at 12:00 pm ET to discuss its fourth quarter and full year 2025 financial results.
2024-10-18
Leadership changes
American Shared Hospital Services (NYSE American: AMS) announced the promotion of Ranjit Pradhan to Senior Vice President of Sales and Marketing.
2024-05-09
M&A
"American Shared Hospital Services (NYSE American: AMS) (the \"Company\"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced the closing of its acquisition of a 60% majority equity interest in the Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, both Rhode Island limited liability corporations (the \"Companies\") as well as certain payor contracts, from the Chapter 11 Bankruptcy Estate of GenesisCare USA, Inc., a Florida corporation, for a purchase price of $2.85 million."

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Medical Laboratories Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary medical laboratories news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

medical laboratory market

4 sources83.6% extraction confidence

2023 extracted base$16.36B

2027 extracted forecast$16.36B

Implied source CAGR12.6%

Understanding current healthcare trendspatient needsadvancements in medical technology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, ASEAN, Asia Pacific. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Medical Laboratories news pulse

74,006available Prism news records

Latest 12m volume+8.4%32238 vs 29751 records

Positive classified tone64.3%+5.4 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching laboratory, medical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,806

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,582

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Understanding current healthcare trends

4 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,806 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,614 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Economic-cycle exposure

6,746 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.4% news volume

The latest 12 months contain 32,238 matched records versus 29,751 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

64.3% positive · +5.4pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 8071 (Medical Laboratories), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 6–13. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Medical Laboratories Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Biodesix leads the readiness ranking

Its Prism readiness score is 53/100, the highest in this five-company comparison.

Open Biodesix in Companies Radar

Scale and margin leadership sit with Veracyte and Veracyte

Veracyte has the largest displayed latest revenue at $0.52B; Veracyte has the widest displayed latest margin at 12.8%.

Open Veracyte in Companies Radar

Comparisons

Strongest versus weakest available price path

Veracyte is -7.0% for its five-year window; Biodesix is -84.0% for its five-year window.

Open Veracyte in Companies Radar Open Biodesix in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.52B for Veracyte to $0.03B for American Shared Hospital Services. Entity and filing-period labels remain visible on the company cards.

Open Veracyte in Companies Radar Open American Shared Hospital Services in Companies Radar

Anomalies

Biodesix has the widest attention-readiness rank gap

It ranks #4 by measured news attention (17.9%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Biodesix in Companies Radar

Castle Biosciences shows a price-operating divergence to inspect

Its displayed filing-revenue change is +265.9% while its available monthly-close return is -50.3%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Castle Biosciences in Companies Radar

Explanations

Attention measures coverage volume, not quality

Veracyte's 32.6% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Veracyte in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Biodesix's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 53/100 score.

Open Biodesix in Companies Radar

Stress-test the largest divergence before forming a view

Compare Castle Biosciences's profile with Veracyte's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Castle Biosciences in Companies Radar Open Veracyte in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.